Overview

A Phase II Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Status:
Not yet recruiting
Trial end date:
2025-05-29
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open label phase II clinical study to evaluate the safety and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.
Phase:
Phase 2
Details
Lead Sponsor:
Akeso